{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T21:57:14Z","timestamp":1794952634412,"version":"4.9.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["772376-EScORIAL"],"award-info":[{"award-number":["772376-EScORIAL"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIHR Maudsley Biomedical Research Centre, United Kingdom","id":[{"id":"https:\/\/ror.org\/05fd9ct06","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009362","name":"South London and Maudsley NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009362","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000764","name":"King's College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000764","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterised by considerable heterogeneity in both its underlying biological mechanisms and clinical presentation. High-dimensional transcriptomic datasets offer an opportunity to characterise this variation at the molecular level; however, traditional statistical methods struggle with their scale and complexity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main body<\/jats:title>\n                    <jats:p>Machine learning approaches can reduce dimensionality and uncover latent patterns, enabling the identification of molecular subtypes that may refine prognosis and support patient stratification. Recent transcriptomic studies employing unsupervised machine learning have identified ALS subtypes with distinct molecular and clinical characteristics. Redefining ALS into more homogeneous molecular and clinical subtypes could transform all areas of ALS research by supporting novel experimental designs and precision medicine approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this review, we summarise and critically assess these studies, discussing their findings, strengths, and limitations, and highlighting research gaps and challenges that must be addressed to enable their translation into biomedical and clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-026-04725-y","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T10:48:39Z","timestamp":1771843719000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Classification of ALS molecular subtypes: a literature review on machine learning applications and their clinical value"],"prefix":"10.1186","volume":"24","author":[{"given":"John K.","family":"Jammal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban A.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammar","family":"Al-Chalabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Iacoangeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"issue":"2","key":"4725_CR1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/NEJMra1603471","volume":"377","author":"RH Brown","year":"2017","unstructured":"Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. N Engl J Med. 2017;377(2):162\u201372.","journal-title":"N Engl J Med"},{"issue":"9","key":"4725_CR2","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/s41576-023-00592-y","volume":"24","author":"F Akcimen","year":"2023","unstructured":"Akcimen F, Lopez ER, Landers JE, Nath A, Chio A, Chia R, et al. Amyotrophic lateral sclerosis: translating genetic discoveries into therapies. Nat Rev Genet. 2023;24(9):642\u201358.","journal-title":"Nat Rev Genet"},{"key":"4725_CR3","doi-asserted-by":"publisher","first-page":"17071","DOI":"10.1038\/nrdp.2017.71","volume":"3","author":"O Hardiman","year":"2017","unstructured":"Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071.","journal-title":"Nat Rev Dis Primers"},{"key":"4725_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jns.2019.02.030","volume":"399","author":"S Mathis","year":"2019","unstructured":"Mathis S, Goizet C, Soulages A, Vallat JM, Masson GL. Genetics of amyotrophic lateral sclerosis: A review. J Neurol Sci. 2019;399:217\u201326.","journal-title":"J Neurol Sci"},{"issue":"3\u20134","key":"4725_CR5","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/21678421.2018.1562553","volume":"20","author":"A Iacoangeli","year":"2019","unstructured":"Iacoangeli A, Al Khleifat A, Sproviero W, Shatunov A, Jones AR, Opie-Martin S, et al. ALSgeneScanner: a pipeline for the analysis and interpretation of DNA sequencing data of ALS patients. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(3\u20134):207\u201315.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"4","key":"4725_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108323","volume":"33","author":"A Iacoangeli","year":"2020","unstructured":"Iacoangeli A, Lin T, Al Khleifat A, Jones AR, Opie-Martin S, Coleman JRI, et al. Genome-wide Meta-analysis Finds the ACSL5-ZDHHC6 Locus Is Associated with ALS and Links Weight Loss to the Disease Genetics. Cell Rep. 2020;33(4):108323.","journal-title":"Cell Rep"},{"issue":"12","key":"4725_CR7","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41588-021-00973-1","volume":"53","author":"W van Rheenen","year":"2021","unstructured":"van Rheenen W, van der Spek RAA, Bakker MK, van Vugt J, Hop PJ, Zwamborn RAJ, et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat Genet. 2021;53(12):1636\u201348.","journal-title":"Nat Genet"},{"issue":"10","key":"4725_CR8","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1136\/jnnp-2024-335364","volume":"96","author":"A Iacoangeli","year":"2025","unstructured":"Iacoangeli A, Dilliott AA, Al Khleifat A, Andersen PM, Basak NA, Cooper-Knock J, et al. Oligogenic structure of amyotrophic lateral sclerosis has genetic testing, counselling and therapeutic implications. J Neurol Neurosurg Psychiatry. 2025;96(10):928\u201336.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"4725_CR9","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.1093\/brain\/awac279","volume":"145","author":"PR Mehta","year":"2022","unstructured":"Mehta PR, Iacoangeli A, Opie-Martin S, van Vugt J, Al Khleifat A, Bredin A, et al. The impact of age on genetic testing decisions in amyotrophic lateral sclerosis. Brain. 2022;145(12):4440\u20137.","journal-title":"Brain"},{"key":"4725_CR10","doi-asserted-by":"crossref","unstructured":"Eshima J, O'Connor SA, Marschall E, Consortium NA, Bowser R, Plaisier CL, et al. Molecular subtypes of ALS are associated with differences in patient prognosis. Nat Commun. 2023;14(1):95.","DOI":"10.1038\/s41467-022-35494-w"},{"issue":"1","key":"4725_CR11","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s40478-023-01686-8","volume":"11","author":"H Marriott","year":"2023","unstructured":"Marriott H, Kabiljo R, Hunt GP, Khleifat AA, Jones A, Troakes C, et al. Unsupervised machine learning identifies distinct ALS molecular subtypes in post-mortem motor cortex and blood expression data. Acta Neuropathol Commun. 2023;11(1):208.","journal-title":"Acta Neuropathol Commun"},{"key":"4725_CR12","doi-asserted-by":"crossref","unstructured":"O'Neill K, Shaw R, Bolger I, Consortium NA, Tam OH, Phatnani H, et al. ALS molecular subtypes are a combination of cellular and pathological features learned by deep multiomics classifiers. Cell Rep. 2025;44(3):115402.","DOI":"10.1016\/j.celrep.2025.115402"},{"key":"4725_CR13","doi-asserted-by":"crossref","unstructured":"Tam OH, Rozhkov NV, Shaw R, Kim D, Hubbard I, Fennessey S, et al. Postmortem Cortex Samples Identify Distinct Molecular Subtypes of ALS: Retrotransposon Activation, Oxidative Stress, and Activated Glia. Cell Rep. 2019;29(5):1164\u201377 e5.","DOI":"10.1016\/j.celrep.2019.09.066"},{"issue":"6","key":"4725_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12943","volume":"49","author":"N Grima","year":"2023","unstructured":"Grima N, Liu S, Southwood D, Henden L, Smith A, Lee A, et al. RNA sequencing of peripheral blood in amyotrophic lateral sclerosis reveals distinct molecular subtypes: Considerations for biomarker discovery. Neuropathol Appl Neurobiol. 2023;49(6):e12943.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"4725_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2019.6","volume":"6","author":"S Zucca","year":"2019","unstructured":"Zucca S, Gagliardi S, Pandini C, Diamanti L, Bordoni M, Sproviero D, et al. RNA-Seq profiling in peripheral blood mononuclear cells of amyotrophic lateral sclerosis patients and controls. Sci Data. 2019;6:190006.","journal-title":"Sci Data"},{"issue":"6","key":"4725_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198874","volume":"13","author":"W van Rheenen","year":"2018","unstructured":"van Rheenen W, Diekstra FP, Harschnitz O, Westeneng HJ, van Eijk KR, Saris CGJ, et al. Whole blood transcriptome analysis in amyotrophic lateral sclerosis: A biomarker study. PLoS ONE. 2018;13(6):e0198874.","journal-title":"PLoS ONE"},{"key":"4725_CR17","doi-asserted-by":"crossref","unstructured":"Iacoangeli A, Fogh I, Selvackadunco S, Topp SD, Shatunov A, van Rheenen W, et al. SCFD1 expression quantitative trait loci in amyotrophic lateral sclerosis are differentially expressed. Brain Commun. 2021;3(4):fcab236.","DOI":"10.1093\/braincomms\/fcab236"},{"issue":"1","key":"4725_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93742-3","volume":"11","author":"AR Jones","year":"2021","unstructured":"Jones AR, Iacoangeli A, Adey BN, Bowles H, Shatunov A, Troakes C, et al. A HML6 endogenous retrovirus on chromosome 3 is upregulated in amyotrophic lateral sclerosis motor cortex. Sci Rep. 2021;11(1):14283.","journal-title":"Sci Rep"},{"issue":"1","key":"4725_CR19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1017\/cjn.2016.284","volume":"44","author":"H Blasco","year":"2017","unstructured":"Blasco H, Garcon G, Patin F, Veyrat-Durebex C, Boyer J, Devos D, et al. Panel of Oxidative Stress and Inflammatory Biomarkers in ALS: A Pilot Study. Can J Neurol Sci. 2017;44(1):90\u20135.","journal-title":"Can J Neurol Sci"},{"issue":"15","key":"4725_CR20","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1096\/fasebj.13.15.2318","volume":"13","author":"D Liu","year":"1999","unstructured":"Liu D, Wen J, Liu J, Li L. The roles of free radicals in amyotrophic lateral sclerosis: reactive oxygen species and elevated oxidation of protein, DNA, and membrane phospholipids. FASEB J. 1999;13(15):2318\u201328.","journal-title":"FASEB J"},{"issue":"5","key":"4725_CR21","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1097\/WCO.0000000000001279","volume":"37","author":"AD Calma","year":"2024","unstructured":"Calma AD, Pavey N, Menon P, Vucic S. Neuroinflammation in amyotrophic lateral sclerosis: pathogenic insights and therapeutic implications. Curr Opin Neurol. 2024;37(5):585\u201392.","journal-title":"Curr Opin Neurol"},{"key":"4725_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2017.00242","volume":"9","author":"MC Geloso","year":"2017","unstructured":"Geloso MC, Corvino V, Marchese E, Serrano A, Michetti F, D\u2019Ambrosi N. The dual role of microglia in ALS: mechanisms and therapeutic approaches. Front Aging Neurosci. 2017;9:242.","journal-title":"Front Aging Neurosci"},{"key":"4725_CR23","doi-asserted-by":"crossref","unstructured":"Cao MC, Scotter EL. Transcriptional targets of amyotrophic lateral sclerosis\/frontotemporal dementia protein TDP-43 - meta-analysis and interactive graphical database. Dis Model Mech. 2022;15(9):dmm049418.","DOI":"10.1242\/dmm.049418"},{"key":"4725_CR24","doi-asserted-by":"crossref","unstructured":"Seki S, Kitaoka Y, Kawata S, Nishiura A, Uchihashi T, Hiraoka SI, et al. Characteristics of sensory neuron dysfunction in amyotrophic lateral sclerosis (ALS): potential for ALS therapy. Biomedicines. 2023;11(11):2967.","DOI":"10.3390\/biomedicines11112967"},{"key":"4725_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.723871","volume":"13","author":"E Zuccaro","year":"2021","unstructured":"Zuccaro E, Piol D, Basso M, Pennuto M. Motor neuron diseases and neuroprotective peptides: a closer look to neurons. Front Aging Neurosci. 2021;13:723871.","journal-title":"Front Aging Neurosci"},{"issue":"17","key":"4725_CR26","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1093\/hmg\/ddx233","volume":"26","author":"M Prudencio","year":"2017","unstructured":"Prudencio M, Gonzales PK, Cook CN, Gendron TF, Daughrity LM, Song Y, et al. Repetitive element transcripts are elevated in the brain of C9orf72 ALS\/FTLD patients. Hum Mol Genet. 2017;26(17):3421\u201331.","journal-title":"Hum Mol Genet"},{"issue":"10","key":"4725_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0258291","volume":"16","author":"B Valdebenito-Maturana","year":"2021","unstructured":"Valdebenito-Maturana B, Arancibia E, Riadi G, Tapia JC, Carrasco M. Locus-specific analysis of transposable elements during the progression of ALS in the SOD1G93A mouse model. PLoS ONE. 2021;16(10):e0258291.","journal-title":"PLoS ONE"},{"issue":"Suppl","key":"4725_CR28","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0022-510X(95)00087-I","volume":"129","author":"ME Westarp","year":"1995","unstructured":"Westarp ME, Ferrante P, Perron H, Bartmann P, Kornhuber HH. Sporadic ALS\/MND: a global neurodegeneration with retroviral involvement? J Neurol Sci. 1995;129(Suppl):145\u20137.","journal-title":"J Neurol Sci"},{"issue":"Suppl","key":"4725_CR29","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/0022-510X(95)00086-H","volume":"129","author":"P Ferrante","year":"1995","unstructured":"Ferrante P, Westarp ME, Mancuso R, Puricelli S, Westarp MP, Mini M, et al. HTLV tax-rex DNA and antibodies in idiopathic amyotrophic lateral sclerosis. J Neurol Sci. 1995;129(Suppl):140\u20134.","journal-title":"J Neurol Sci"},{"issue":"6","key":"4725_CR30","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1097\/00001756-199306000-00056","volume":"4","author":"ME Westarp","year":"1993","unstructured":"Westarp ME, Bartmann P, Rossler J, Geiger E, Westphal KP, Schreiber H, et al. Antiretroviral therapy in sporadic adult amyotrophic lateral sclerosis. NeuroReport. 1993;4(6):819\u201322.","journal-title":"NeuroReport"},{"issue":"4","key":"4725_CR31","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/1096-9071(200008)61:4<527::AID-JMV17>3.0.CO;2-A","volume":"61","author":"WD Andrews","year":"2000","unstructured":"Andrews WD, Tuke PW, Al-Chalabi A, Gaudin P, Ijaz S, Parton MJ, et al. Detection of reverse transcriptase activity in the serum of patients with motor neurone disease. J Med Virol. 2000;61(4):527\u201332.","journal-title":"J Med Virol"},{"issue":"1","key":"4725_CR32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/ana.22149","volume":"69","author":"R Douville","year":"2011","unstructured":"Douville R, Liu J, Rothstein J, Nath A. Identification of active loci of a human endogenous retrovirus in neurons of patients with amyotrophic lateral sclerosis. Ann Neurol. 2011;69(1):141\u201351.","journal-title":"Ann Neurol"},{"issue":"7\u20138","key":"4725_CR33","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1080\/21678421.2019.1632899","volume":"20","author":"J Gold","year":"2019","unstructured":"Gold J, Rowe DB, Kiernan MC, Vucic S, Mathers S, van Eijk RPA, et al. Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(7\u20138):595\u2013604.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"3","key":"4725_CR34","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1136\/jnnp-2018-319210","volume":"90","author":"AL Savage","year":"2019","unstructured":"Savage AL, Schumann GG, Breen G, Bubb VJ, Al-Chalabi A, Quinn JP. Retrotransposons in the development and progression of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(3):284\u201393.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4725_CR35","doi-asserted-by":"crossref","unstructured":"Bond S, Saxena S, Sierra-Delgado JA. Microglia in ALS: insights into mechanisms and therapeutic potential. Cells. 2025;14(6):421.","DOI":"10.3390\/cells14060421"},{"issue":"10492","key":"4725_CR36","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/S0140-6736(25)00262-4","volume":"405","author":"G Bensimon","year":"2025","unstructured":"Bensimon G, Leigh PN, Tree T, Malaspina A, Payan CA, Pham HP, et al. Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial. Lancet. 2025;405(10492):1837\u201350.","journal-title":"Lancet"},{"key":"4725_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102844","volume":"59","author":"W Camu","year":"2020","unstructured":"Camu W, Mickunas M, Veyrune JL, Payan C, Garlanda C, Locati M, et al. Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial. EBioMedicine. 2020;59:102844.","journal-title":"EBioMedicine"},{"issue":"9","key":"4725_CR38","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1093\/brain\/awad075","volume":"146","author":"A Catanese","year":"2023","unstructured":"Catanese A, Rajkumar S, Sommer D, Masrori P, Hersmus N, Van Damme P, et al. Multiomics and machine-learning identify novel transcriptional and mutational signatures in amyotrophic lateral sclerosis. Brain. 2023;146(9):3770\u201382.","journal-title":"Brain"},{"key":"4725_CR39","doi-asserted-by":"crossref","unstructured":"Valdebenito-Maturana B, Rojas-Tapia MI, Carrasco M, Tapia JC. Dysregulated expression of transposable elements in TDP-43(M337V) human motor neurons that recapitulate amyotrophic lateral sclerosis in vitro. Int J Mol Sci. 2022;23(24):16222.","DOI":"10.3390\/ijms232416222"},{"issue":"11","key":"4725_CR40","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1172\/JCI139741","volume":"130","author":"M Prudencio","year":"2020","unstructured":"Prudencio M, Humphrey J, Pickles S, Brown AL, Hill SE, Kachergus JM, et al. Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. J Clin Invest. 2020;130(11):6080\u201392.","journal-title":"J Clin Invest"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04725-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04725-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04725-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T15:04:04Z","timestamp":1774883044000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04725-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4725"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04725-y","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is a literature review and did not involve human participants, animal experiments, or new data collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"183"}}